文献速递主动脉疾病

常规肠系膜下动脉栓塞在血管腔内动脉瘤修复术前并非必要

Routine Inferior Mesenteric Artery Embolisation is Unnecessary Before Endovascular Aneurysm Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-11-09

本研究回顾性比较两中心2005至2015年EVAR患者,A中心常规尝试肠系膜下动脉栓塞,B中心不处理该动脉。A组395例,B组337例,平均随访70个月与68.2个月。因II型内漏再干预率两组无显著差异(12.9%对10.4%,p=.29),常规栓塞策略未见显著临床获益。

要点

  • 常规EVAR术前肠系膜下动脉栓塞组与不处理组因II型内漏再干预率无显著差异(12.9%对10.4%,p=.29)。
  • 两组EVAR相关再干预率相似(24.1%对24.6%,p=.93),瘤囊显著增大率亦无显著差异(20.3%对19.6%,p=.82)。
  • 作者认为常规栓塞肠系膜下动脉未见显著临床获益,应放弃该策略。

核心结论

  • 常规肠系膜下动脉栓塞策略似乎未产生任何显著临床获益,因此应放弃该策略。

研究设计与样本

  • 回顾性分析两中心2005至2015年期间接受EVAR治疗的患者数据,比较A中心常规尝试肠系膜下动脉栓塞策略与B中心不处理肠系膜下动脉策略。
  • A中心策略治疗395例患者,B中心策略治疗337例患者。

主要发现

  • A中心395例中肠系膜下动脉通畅268例(67.8%),实施栓塞164例(41.5%);B中心337例中通畅279例(82.8%),其中仅2例(0.6%)实施栓塞。
  • A中心平均随访70个月,B中心平均随访68.2个月。
  • 因II型内漏再干预率A中心为12.9%,B中心为10.4%(p=.29);为闭塞通畅肠系膜下动脉的再干预率A中心为2.0%,B中心为4.7%(p=.039)。
  • EVAR相关再干预率A中心为24.1%,B中心为24.6%(p=.93);瘤囊显著增大率A中心为20.3%,B中心为19.6%(p=.82)。
  • 动脉瘤破裂率A中心为2.5%,B中心为2.1%(p=.69);开放转换率A中心为1.0%,B中心为1.5%(p=.40)。

临床怎么用

  • 作者认为常规EVAR术前栓塞肠系膜下动脉的策略应被放弃。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A type II endoleak is the most common complication during surveillance after endovascular aneurysm repair (EVAR), and a patent inferior mesenteric artery (IMA) is a known risk factor for an endoleak. The effect of routine IMA embolisation prior to EVAR on overall outcome is unknown. The aim of the study was to compare two strategies: routine attempted IMA embolisation prior to EVAR (strategy in centre A) and leaving the IMA untouched (strategy in centre B). METHODS: Patients were treated with EVAR in two centres during the period 2005 - 2015, and the data were reviewed retrospectively. The primary endpoints were re-intervention rate due to type II endoleaks and the late IMA embolisation rate. Secondary endpoints included EVAR related re-intervention, sac enlargement, aneurysm rupture, and open conversion rates. RESULTS: Strategy A was used to treat 395 patients. The IMA was patent in 268 (67.8%) patients, and embolisation was performed in 164 (41.5%). The corresponding figures for strategy B were 337 patients with 279 (82.8%) patent IMAs, two (0.6%) of which were embolised. The mean duration of follow up was 70 months for strategy A and 68.2 months for strategy B. The re-intervention rates due to a type II endoleak were 12.9% and 10.4%, respectively (p = .29), with no significant difference in the rate of re-interventions to occlude a patent IMA (2.0% and 4.7%, respectively; p = .039). The EVAR related re-intervention rate was similar, regardless of strategy (24.1% and 24.6%, respectively; p = .93). Significant sac enlargement was seen in 20.3% of cases treated with strategy A and in 19.6% treated with strategy B (p = .82). The rupture and conversion rates were 2.5% and 2.1% (p = .69) and 1.0% and 1.5% (p = .40), respectively. CONCLUSION: The strategy of routinely embolising the IMA does not seem to yield any significant clinical benefit and should therefore be abandoned.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Väärämäki S, Viitala H, Laukontaus S, et al. Routine Inferior Mesenteric Artery Embolisation is Unnecessary Before Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2022. PMID: 36334900. doi:10.1016/j.ejvs.2022.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。